Bearish
Johnson & Johnson's Q3 2026 earnings miss expectations; stock drops 5.7%
Johnson & Johnson's Q3 2026 earnings report revealed a 5.7% decline in stock price, despite exceeding earnings expectations. The downturn was primarily due to underperformance in the medical devices division, influenced by geopolitical tensions in the Middle East.
Key points
- Medical devices sales fell short of expectations, impacted by Middle East tensions.
- Pharmaceutical sales rose 7.7%, driven by strong performance of Tremfya.
- Company raised full-year 2026 sales and adjusted EPS guidance.
- Analysts maintain a 'Buy' rating with an average 12-month price target of $279.41.
Sources
- Stocks Struggle Ahead of September CPI Report: Stock Market TodayKiplinger · October 13, 2026
- Johnson & Johnson (JNJ) Stock Price & OverviewStockAnalysis.com · October 16, 2026
- Johnson & Johnson (JNJ) Stock News & UpdatesStockTitan · October 16, 2026
- Johnson & Johnson's Stock Price at Critical Turning PointMarketBeat · January 24, 2024
AI-generated from public news sources. Not financial advice.
